Heart-on-a-chip Systems

Bułka, Magdalena; Jastrzębska, Elżbieta

doi:10.1007/978-3-319-70685-6_8

Cited by 3 publications

(4 citation statements)

References 110 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The heart is an important organ that maintains homeostasis in the body. The supply of nutrients to organs is mainly managed by specialized cells such as cardiomyocytes, which are responsible for heart contractions [ 41 ]. Myocardial infarction, hypertrophy, and atherosclerosis are some of the major diseases with high mortality around the world.…”

Section: Organs On-a-chipmentioning

confidence: 99%

Novel Strategies in Artificial Organ Development: What Is the Future of Medicine?

Klak¹,

Bryniarski²,

Kowalska³

et al. 2020

Micromachines

View full text Add to dashboard Cite

The technology of tissue engineering is a rapidly evolving interdisciplinary field of science that elevates cell-based research from 2D cultures through organoids to whole bionic organs. 3D bioprinting and organ-on-a-chip approaches through generation of three-dimensional cultures at different scales, applied separately or combined, are widely used in basic studies, drug screening and regenerative medicine. They enable analyses of tissue-like conditions that yield much more reliable results than monolayer cell cultures. Annually, millions of animals worldwide are used for preclinical research. Therefore, the rapid assessment of drug efficacy and toxicity in the early stages of preclinical testing can significantly reduce the number of animals, bringing great ethical and financial benefits. In this review, we describe 3D bioprinting techniques and first examples of printed bionic organs. We also present the possibilities of microfluidic systems, based on the latest reports. We demonstrate the pros and cons of both technologies and indicate their use in the future of medicine.

show abstract

Section: Organs On-a-chipmentioning

confidence: 99%

Novel Strategies in Artificial Organ Development: What Is the Future of Medicine?

Klak¹,

Bryniarski²,

Kowalska³

et al. 2020

Micromachines

View full text Add to dashboard Cite

show abstract

“…constructs [219][220][221][222]. This is mainly because direct electrical stimulation mediates the release and re-uptake of Ca 2+ ions via the sarcoplasmic reticulum, which directly influences the contractile function of CMs.…”

Section: Tablementioning

confidence: 99%

“…Because of these characteristics, microphysiological platforms can be remarkably useful in the determination of the safety, efficacy, and side effects of drugs for the treatment of cardiovascular and other diseases. This in turn can dramatically reduce the costs associated with preclinical assessment, development, production, and implementation of therapeutic drugs [222]. In this regard, biological variables such as cell viability, expression of cardiac markers, rate and synchronicity of CM contraction, and several other functional parameters can be evaluated to establish optimal drug dosages and regimens [181,222].…”

Section: Tablementioning

confidence: 99%

“…This in turn can dramatically reduce the costs associated with preclinical assessment, development, production, and implementation of therapeutic drugs [222]. In this regard, biological variables such as cell viability, expression of cardiac markers, rate and synchronicity of CM contraction, and several other functional parameters can be evaluated to establish optimal drug dosages and regimens [181,222]. For instance, Agarwal et al developed a microengineered heart-on-a-chip system to investigate the inotropic effect of isoproterenol (a non-selective β-adrenergic agonist used for the treatment of bradycardia) on the contractility of neonatal rat ventricular myocytes, using a 3D multicellular culture system [238].…”

Section: Tablementioning

confidence: 99%

See 1 more Smart Citation

Biomimetic cardiovascular platforms for in vitro disease modeling and therapeutic validation

et al. 2019

View full text Add to dashboard Cite

Bioengineered tissues have become increasingly more sophisticated owing to recent advancements in the fields of biomaterials, microfabrication, microfluidics, genetic engineering, and stem cell and developmental biology. In the coming years, the ability to engineer artificial constructs that accurately mimic the compositional, architectural, and functional properties of human tissues, will profoundly impact the therapeutic and diagnostic aspects of the healthcare industry. In this regard, bioengineered cardiac tissues are of particular importance due to the extremely limited ability of the myocardium to self-regenerate, as well as the remarkably high mortality associated with cardiovascular diseases worldwide. As novel microphysiological systems make the transition from bench to bedside, their implementation in high throughput drug screening, personalized diagnostics, disease modeling, and targeted therapy validation will bring forth a paradigm shift in the clinical management of cardiovascular diseases. Here, we will review the current state of the art in experimental in vitro platforms for next generation diagnostics and therapy validation. We will describe recent advancements in the development of smart biomaterials, biofabrication techniques, and stem cell engineering, aimed at recapitulating cardiovascular function at the tissue- and organ levels. In addition, integrative and multidisciplinary approaches to engineer biomimetic cardiovascular constructs with unprecedented human and clinical relevance will be discussed. We will comment on the implementation of these platforms in high throughput drug screening, in vitro disease modeling and therapy validation. Lastly, future perspectives will be provided on how these biomimetic platforms will aid in the transition towards patient centered diagnostics, and the development of personalized targeted therapeutics.

show abstract

Human Organs‐on‐Chips: A Review of the State‐of‐the‐Art, Current Prospects, and Future Challenges

et al. 2021

View full text Add to dashboard Cite

New emerging technologies, remarkably miniaturized 3D organ models and microfluidics, enable simulation of the real in vitro microenvironment ex vivo more closely. There are many fascinating features of innovative organ‐on‐a‐chip (OOC) technology, including the possibility of integrating semipermeable and/or stretchable membranes, creating continuous perfusion of fluids into microchannels and chambers (while maintaining laminar flow regime), embedding microdevices like microsensors, microstimulators, micro heaters, or different cell lines, along with other 3D cell culture technologies. OOC systems are designed to imitate the structure and function of human organs, ranging from breathing lungs to beating hearts. This technology is expected to be able to revolutionize cell biology studies, personalized precision medicine, drug development process, and cancer diagnosis/treatment. OOC systems can significantly reduce the cost associated with tedious drug development processes and the risk of adverse drug reactions in the body, which makes drug screening more effective. The review mainly focus on presenting an overview of the several previously developed OOC systems accompanied by subjects relevant to pharmacy‐, cancer‐, and placenta‐on‐a‐chip. The challenging issues and opportunities related to these systems are discussed, along with a future perspective for this technology.

show abstract

Heart-on-a-chip Systems

Cited by 3 publications

References 110 publications

Novel Strategies in Artificial Organ Development: What Is the Future of Medicine?

Novel Strategies in Artificial Organ Development: What Is the Future of Medicine?

Biomimetic cardiovascular platforms for in vitro disease modeling and therapeutic validation

Human Organs‐on‐Chips: A Review of the State‐of‐the‐Art, Current Prospects, and Future Challenges

Contact Info

Product

Resources

About